110 related articles for article (PubMed ID: 35410826)
1. Prognostic Significance of C-reactive Protein in Patients With Non-metastatic Papillary Renal Cell Carcinoma: Results from the INternational Marker Consortium for Renal Cancer (INMARC) Cohort.
Toide M; Saito K; Yasuda Y; Tanaka H; Fukuda S; Patil D; Cotta BH; Patel SH; Master VA; Derweesh IH; Fujii Y
Clin Genitourin Cancer; 2022 Aug; 20(4):e276-e282. PubMed ID: 35410826
[TBL] [Abstract][Full Text] [Related]
2. C-reactive protein/albumin ratio is a predictive factor for prognosis in patients with metastatic renal cell carcinoma.
Konishi S; Hatakeyama S; Tanaka T; Ikehata Y; Tanaka T; Hamano I; Fujita N; Yoneyama T; Yamamoto H; Yoneyama T; Hashimoto Y; Yoshikawa K; Kawaguchi T; Masumori N; Kitamura H; Ohyama C
Int J Urol; 2019 Oct; 26(10):992-998. PubMed ID: 31342557
[TBL] [Abstract][Full Text] [Related]
3. Elevated preoperative C-reactive protein is associated with renal functional decline and non-cancer mortality in surgically treated renal cell carcinoma: analysis from the INternational Marker Consortium for Renal Cancer (INMARC).
Cotta BH; Meagher MF; Patil D; Saito K; Patel SH; Patel DN; Miller N; Dutt R; Keiner C; Bradshaw AW; Wan F; Eldefrawy A; Yasuda Y; Fujii Y; Master V; Derweesh IH
BJU Int; 2021 Mar; 127(3):311-317. PubMed ID: 32772468
[TBL] [Abstract][Full Text] [Related]
4. Preoperative Elevation of C-Reactive Protein Is a Predictor for Adverse Oncologic Survival Outcomes for Renal Cell Carcinoma: Analysis from the International Marker Consortium Renal Cancer (INMARC).
Patel SH; Derweesh IH; Saito K; Patil D; Meagher MF; Bindayi A; Eldefrawy A; Patel DN; Nasseri R; Yasuda Y; Fujii Y; Master VA
Clin Genitourin Cancer; 2021 Aug; 19(4):e206-e215. PubMed ID: 33773937
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.
Beuselinck B; Vano YA; Oudard S; Wolter P; De Smet R; Depoorter L; Teghom C; Karadimou A; Zucman-Rossi J; Debruyne PR; Van Poppel H; Joniau S; Lerut E; Strijbos M; Dumez H; Paridaens R; Van Calster B; Schöffski P
BJU Int; 2014 Jul; 114(1):81-9. PubMed ID: 24215209
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of Baseline Serum C-Reactive Protein Level in Intermediate-Risk Group Patients With Metastatic Renal-Cell Carcinoma Treated by First-Line Vascular Endothelial Growth Factor-Targeted Therapy.
Takamatsu K; Mizuno R; Omura M; Morita S; Matsumoto K; Shinoda K; Kosaka T; Takeda T; Shinojima T; Kikuchi E; Asanuma H; Oyama M; Mikami S; Oya M
Clin Genitourin Cancer; 2018 Aug; 16(4):e927-e933. PubMed ID: 29678472
[TBL] [Abstract][Full Text] [Related]
7. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
8. C-reactive protein is a predictor of prognosis in renal cell carcinoma patients receiving tyrosine kinase inhibitors: A meta-analysis.
Wang Z; Peng S; Wang A; Xie H; Guo L; Jiang N; Niu Y
Clin Chim Acta; 2017 Dec; 475():178-187. PubMed ID: 29080691
[TBL] [Abstract][Full Text] [Related]
9. Analysis and validation of tissue biomarkers for renal cell carcinoma using automated high-throughput evaluation of protein expression.
Abel EJ; Bauman TM; Weiker M; Shi F; Downs TM; Jarrard DF; Huang W
Hum Pathol; 2014 May; 45(5):1092-9. PubMed ID: 24746216
[TBL] [Abstract][Full Text] [Related]
10. External validation of the albumin, C-reactive protein and lactate dehydrogenase model in patients with metastatic renal cell carcinoma receiving second-line axitinib therapy in a Japanese multi-center cohort.
Tamura K; Osawa T; Takeuchi A; Minami K; Nakai Y; Ueda K; Ozawa M; Uemura M; Sugimoto M; Ohba K; Suzuki T; Anai S; Shindo T; Kusakabe N; Komiyama M; Tanaka K; Yokomizo A; Kohei N; Shinohara N; Miyake H;
Jpn J Clin Oncol; 2021 Apr; 51(5):810-818. PubMed ID: 33479762
[TBL] [Abstract][Full Text] [Related]
11. Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombus.
Kim KH; You D; Jeong IG; Kwon TW; Cho YM; Hong JH; Ahn H; Kim CS
BJU Int; 2012 Dec; 110(11 Pt B):E673-8. PubMed ID: 22973869
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of serum C-reactive protein level prior to second-line treatment in intermediate risk metastatic renal cell carcinoma patients.
Takamatsu K; Mizuno R; Tanaka N; Takeda T; Morita S; Matsumoto K; Kosaka T; Shinojima T; Kikuchi E; Asanuma H; Oyama M; Mikami S; Oya M
Int J Clin Oncol; 2019 Sep; 24(9):1069-1074. PubMed ID: 31065836
[TBL] [Abstract][Full Text] [Related]
13. Overall prognostic impact of C-reactive protein level in patients with metastatic renal cell carcinoma treated with sorafenib.
Fujita T; Nishi M; Tabata K; Matsumoto K; Yoshida K; Iwamura M
Anticancer Drugs; 2016 Nov; 27(10):1028-32. PubMed ID: 27537400
[TBL] [Abstract][Full Text] [Related]
14. Morphologic subtyping as a prognostic predictor for survival in papillary renal cell carcinoma: Type 1 vs. type 2.
Wong ECL; Di Lena R; Breau RH; Pouliot F; Finelli A; Lavallée LT; So A; Tanguay S; Fairey A; Rendon R; Richard PO; Lattouf JB; Kawakami J; Mallick R; Kapoor A
Urol Oncol; 2019 Oct; 37(10):721-726. PubMed ID: 31176614
[TBL] [Abstract][Full Text] [Related]
15. C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab.
Roussel E; Kinget L; Verbiest A; Debruyne PR; Baldewijns M; Van Poppel H; Albersen M; Beuselinck B
Urol Oncol; 2021 Apr; 39(4):239.e17-239.e25. PubMed ID: 33485762
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of C-reactive protein in renal cell carcinoma: a systematic review and meta-analysis.
Hu Q; Gou Y; Sun C; Ding W; Xu K; Gu B; Xia G; Ding Q
Urol Oncol; 2014 Jan; 32(1):50.e1-8. PubMed ID: 24239465
[TBL] [Abstract][Full Text] [Related]
17. Papillary (chromophil) renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases.
Amin MB; Corless CL; Renshaw AA; Tickoo SK; Kubus J; Schultz DS
Am J Surg Pathol; 1997 Jun; 21(6):621-35. PubMed ID: 9199639
[TBL] [Abstract][Full Text] [Related]
18. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
[TBL] [Abstract][Full Text] [Related]
19. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
20. Female Gender Predicts Favorable Prognosis in Patients With Non-metastatic Clear Cell Renal Cell Carcinoma Undergoing Curative Surgery: Results From the International Marker Consortium for Renal Cancer (INMARC).
Fukushima H; Saito K; Yasuda Y; Tanaka H; Patil D; Cotta BH; Patel SH; Master VA; Derweesh IH; Fujii Y
Clin Genitourin Cancer; 2020 Apr; 18(2):111-116.e1. PubMed ID: 32001181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
